# The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART

> **NCT00035893** · PHASE2 · COMPLETED · sponsor: **AIM ImmunoTech Inc.** · enrollment: 40 (actual)

## Conditions studied

- HIV Seropositivity
- HIV Infection

## Interventions

- **DRUG:** poly I-poly C12U

## Key facts

- **NCT ID:** NCT00035893
- **Lead sponsor:** AIM ImmunoTech Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-05
- **Primary completion:** 2006-08
- **Final completion:** 2006-08
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2013-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00035893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00035893, "The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00035893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*